Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

Padcev + Keytruda reach primary endpoint for some bladder cancers, phase III trial shows

Pacdev (enfortumab vedotin), in combination with PD-1 inhibitor Keytruda (pembrolizumab), reached the main goals in a late-stage trial for certain patients with bladder cancer.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Pre- and post-surgery immunotherapy combination shows promise for mesothelioma, Johns Hopkins-led study shows

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg Kimmel Institute for Cancer Immunotherapy.

September 12, 2025

Vol.51 No.33

Clinical Roundup

Cancer Center at Illinois researcher unveils targeting technology for cancer immunotherapy

Hua Wang, an assistant professor in the departments of Material Science & Engineering, Bioengineering, Materials Research Lab, and Biomedical and Translational Sciences, finetunes an important technology in biomaterial chemistry at the Cancer Center at Illinois, which could potentially make way for more potent cancer immunotherapies.

September 12, 2025

Vol.51 No.33

Drugs & Targets

FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer

FDA has approved gemcitabine intravesical system (Inlexzo) for adults with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors. Gemcitabine intravesical system is co-packaged with a urinary catheter and stylet used for insertion through the urinary catheter into the bladder.

September 12, 2025

Vol.51 No.33

Clinical Roundup

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

The MammaPrint, a gene expression profiling test, predicts the benefit of chemotherapy for patients with hormone receptor-positive, HER2-negative early-stage breast cancer, according to findings published in JNCI Cancer Spectrum.

September 05, 2025

Vol.51 No.32

Clinical Roundup

Decipher Prostate Test predicts chemo benefit in metastatic prostate cancer, phase III trial shows

The Decipher Prostate Genomic Classifier predicts which patients with metastatic cancer are likely to benefit from treatment intensification with the chemotherapy docetaxel and which are not likely to benefit and can therefore avoid unnecessary toxicity, according to findings by University College London and Veracyte, Inc., a genomic diagnostic company.

September 05, 2025

Vol.51 No.32

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

YOU MAY BE INTERESTED IN

Padcev + Keytruda reach primary endpoint for some bladder cancers, phase III trial shows

Pre- and post-surgery immunotherapy combination shows promise for mesothelioma, Johns Hopkins-led study shows

Cancer Center at Illinois researcher unveils targeting technology for cancer immunotherapy

FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

Decipher Prostate Test predicts chemo benefit in metastatic prostate cancer, phase III trial shows

Renew today!

Subscriber content

Never miss an issue!

Login